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A B S T R A C T
Background: Many patients with depression fail to achieve remission after several consecutive treatments.
Vitamin D deficiency is prevalent and new research suggests that it may have an impact on mood, primarily
through an effect on neurotransmitters. Numerous observational studies suggest a relationship between low
levels of vitamin D and increased incidence and severity of mood disorders. A small number of pilot studies have
been undertaken but lack rigorous methodology required to draw conclusions about a clinical role for this
nutrient in treatment resistant depression.
Methods: This study was designed as a randomized, double-blind, placebo controlled intervention study ad-
ministering a weekly (bolus) dose of 28 000IU of Vitamin D3 or placebo to 125 patients with non-remitted
depression adjunct to current antidepressant medication. Patients were followed weekly for eight weeks plus a
one month follow up. Outcomes measured included depression severity, serum vitamin D levels and safety. Due
to slow recruitment during the first season, amendments were made. These included extending the age range to
18–75 and removing the requirement for failing to respond to one pharmacologic antidepressant agent. The
protocol was amended to reduce the burden on participants by changing the in-office visits to bi-weekly. Three
additional tertiary psychiatric clinics were also added as trial sites.
Results: Over three recruitment period years (fall/winter), a total of 148 participants completed screening, 24
(16.2%) of whom qualified to participate in the study. Use of too many or no psychiatric medications, comorbid
exclusionary psychiatric conditions, current use of a vitamin D supplement, and lack of participant compensation
were the predominant reasons for ineligibility or unwillingness to participate. 9 participants were successfully
enrolled in the study, 7 (77.8%) of whom completed the trial as per the protocol. After the third season, futility
was declared based on inability to enroll participants. The sample size of enrolled participants (7/125, 5.6%)
lacks power to conduct a full assessment of findings.
Discussion: High accessibility of vitamin D, as well as a growing lack of equipoise in patients and clinicians about
the potential ubiquitous benefits of vitamin D for Canadians, not just for mood disorders, resulted in a large
proportion of ineligible potential participants. Limited funding provided to studies on natural health products
hampered recruitment. The labile and fluctuating nature of non-remitted depression as well as frequent co-
morbid conditions creates additional challenges for conducting trials in this population. Future studies assessing
vitamin D in depression should consider our experiences in design and conduct of research. Innovations in
clinical trial design such as preference trials or accepting patients already using vitamin D but not achieving an
optimal target value are potential solutions to some of these challenges.
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1. Introduction
Depression and other mood disorders are a major health concern
globally with significant impact on quality of life, morbidity, and
mortality. While antidepressant medications are beneficial for some
patients, many fail to achieve remission after several consecutive
treatments.1 A recent Canadian study found that 22% of a large sample
of depressive patients failed to respond to at least two consecutive
antidepressant agents.2 Despite the increasing prevalence of treatment-
resistant depression, significant challenges to psychopharmacology
management remains, with recent guidance documents identifying a
dearth of evidence and limitations to most strategies for optimal man-
agement.3, 4
While most vitamin deficiencies are rare in the developed world,
vitamin D deficiency remains prevalent, likely due to low sun exposure
at northern latitudes, a trend toward increasing indoor activity and
concern about the risks of excess sun exposure.5 New research suggests
that deficiency of vitamin D may have an impact on mood, primarily
through an effect on neurotransmitters.6 Vitamin D is a neurosteroid,
capable of crossing the blood-brain barrier, with physiological effects
on neuroprotection, neuroplasticity, brain development, and regulation
of neurotrophic factors.7 High concentrations of vitamin D receptors on
neurons and glia have been reported in many areas of the brain in-
cluding the hippocampus and cingulate cortex.8 These neurobiological
findings provide support for a plausible mechanism of vitamin D as an
influencer on mood, as well as a potential factor in prevention and
treatment of mood disorders like depression. Still, there remains some
dispute regarding the validity of some of the studies on vitamin D.9
Numerous observational studies suggest a relationship between low
levels of vitamin D and increased incidence and severity of mood dis-
orders.10 A 2013 systematic review and meta-analysis found a statisti-
cally significant inverse relationship between serum vitamin D levels
and the risk of depression when analyzing the observational data.11 A
number of pilot intervention studies have been undertaken to examine
vitamin D’s therapeutic potential and several showed promising results.
Due to small sample sizes,6, 12,13 inadequate control and blinding,6 non-
clinically depressed patient populations 14–18 a diagnosis of seasonal
affective disorder,19 the presence of other comorbidities,20 and use of
assessment tools lacking validation21 these studies lacked rigorous
methodology required to draw conclusions about a clinical role for this
nutrient in treatment resistant depression.
A 2014 systematic review and meta-analysis reported no overall
effect on depressive symptoms when analyzing all of the studies with
depression outcomes.22 However, in subgroup analysis of two of the
studies that enrolled patients with clinically significant depression, the
effect was shown to be a statistically significant decrease in depression
severity. This suggests that the benefit of vitamin D supplementation
may be most significant in a clinically depressed population, however,
the small number of studies conducted indicate that further research is
needed.
Because of the need for adjunctive treatment options, strong epi-
demiological evidence, proposed mechanisms, and preliminary pilot
study data, we sought to complete a randomized, controlled trial using
vitamin D as an adjunctive therapy in patients with non-remitted de-
pression to see if improvements in depression would occur.
2. Methods
2.1. Study design
This study was designed as a pilot randomized, double-blind, pla-
cebo controlled, parallel intervention study in 125 patients with non-
remitted depression. Patients were randomized to either vitamin D
supplementation or placebo (allocation ratio 1:1). Enrollment and trial
participation took place during the fall and winter months (October to
April, inclusive) to minimize natural vitamin D from sun exposure. The
study was registered at ClinicalTrials.Gov (NCT02072187). Funding
was provided by a competitive grant obtained from the Lotte and John
Hecht Foundation. Ethical approval and oversight was provided by an
independent IRB (Optimum) and the REB of the Canadian College of
Naturopathic Medicine. Permission to conduct the study was given by
Health Canada.
Patients completed a telephone screen followed by a screening visit
which included informed consent, the M.I.N.I. International
Neuropsychiatric Interview (MINI), assessment of serum vitamin D le-
vels (25(OH)D) and liver and kidney function tests, collection of social
history and demographic information, medical, medication and psy-
chiatric history, assessment of vital signs, completion of a physical ex-
amination. Subsequently, participants were followed weekly for eight
weeks plus a one month post-intervention follow up. Each visit included
an assessment of efficacy through the use of validated questionnaires
and an assessment of safety.
Randomization was completed centrally through computer genera-
tion. Simple randomization (i.e. virtual coin flip) was used to determine
group allocation for each participant. The only person aware of the
allocation was a pharmacist. The pharmacist labeled the study product
with sequential numbers which corresponded to participant number
and followed the allocation sequence. A back up copy of the random
allocation sequence was kept in the clinic in a sealed envelope. The
pharmacist had no contact with study participants.
2.2. Participant selection
Eligible participants were 18–65 years of age who met criteria for
major depressive disorder (score of greater than 7 on the Hamilton
Depression Scale) after treatment of at least 8 weeks with an adequate
dose of a single first line pharmacological antidepressant agent.
Exclusion criteria included: any comorbid Axis I disorder (with the
exception of comorbid anxiety disorders if MDD was deemed to be the
primary diagnosis), cognitive disorders, risk of suicide, formal psy-
chotherapy commenced in the 30 days prior to screening, use of any
other psychiatric medications (apart from a short half-life hypnotic
used as needed for insomnia), history of parathyroid disease, kidney
stones, or other serious medical illness, pregnancy or current breast-
feeding, use of natural health products deemed to have antidepressant
effects or supplementation of vitamin D at a dose greater than 200IU
per day in the past 6 months. Lastly, patients were excluded if baseline
serum vitamin D was greater than 150 nmol/L.
Participants were able to withdraw their consent at any time, and
were eligible to be withdrawn from the study if, on the basis of the
study clinician’s subjective assessment, the participant’s depression was
deemed to have seriously worsened or a risk of suicide became ap-
parent. The clinician was aware of participants’ identity and past
medical history in order to select a rescue medication and inform an
individualized course of treatment if needed. A data safety monitoring
board (DSMB) was in place to address adverse events in the study, as
well as provide additional advice and oversight of any participant
withdrawals.
The study was conducted at the START Clinic, a tertiary psychiatry
clinic in Toronto, Ontario, Canada. Participants were recruited from the
patient database at the START Clinic, as well as new referrals to the
clinic. Letters were mailed to Medical Doctors in the surrounding area
with an invitation to refer non-remitted depression patients.
Additionally, online classified postings and print advertisements were
created. Additional trial sites were located at the Chatham-Kent Health
Alliance in Chatham, Ontario, Canada, a small community hospital, and
Eden Mental Health Centre in Winkler, Manitoba, Canada, a small
psychiatric hospital providing inpatient and outpatient services.
2.3. Intervention
The intervention was a weekly bolus dose of 28 000IU of Vitamin
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D3 (cholecalciferol), the equivalent of 4000IU per day, or placebo. The
vitamin D formula contained the following non-medicinal ingredients:
water, gum arabic, and sesame oil. The placebo formula contained all
non-medicinal ingredients but no vitamin D and appeared, smelled, and
tasted the same as the active formula. The formula was a liquid and
dispensed on a disposable spoon by the study coordinator at each
weekly study visit. The participants continued to take their previously
prescribed anti-depressant medication for the duration of the study
without changing the dose. They were not permitted to begin a new
medication or any nutritional supplement with a theoretical effect on
depression.
2.4. Outcomes
The primary outcome was effect on depression, measured through
patients’ responses on the Beck Depression Inventory-II (BDI-II) and the
Fawcett-Clark Pleasure Capacity Scale (FCPS). Additionally, the Beck
Anxiety Inventory (BAI), Intolerance of Uncertainty Scale (IUS) and
Sheehan Disability Scale (SDS) were used to assess other aspects of
mental wellbeing and quality of life.
2.5. Instruments
Beck Depression Inventory-II (BDI-II): The BDI-II is a 21-item self-
report measure designed to assess the presence and severity of de-
pression. Items are based on DSM-IV diagnostic criteria for MDD and
are rated on a 4-point present-state severity scale.23 Test items describe
possible feelings within the past two weeks, and subjects are asked to
rate how much these statements parallel their own feelings using a four-
point Likert scale (higher scores coinciding with a greater degree of
depression). The scores range from 0 to 63, with scores of 0–13 in-
dicating minimal depression, 14–19 mild depression, 20–28 moderate
depression, and 29–63 severe depression. The BDI II has demonstrated
excellent psychometric properties with good internal consistency
(alpha =0.91)24.
Intolerance of Uncertainty Scale (IUS): The IUS assesses intolerance
to uncertainty, and follows a four-factor structure representing the
ideas that uncertainty i) is stressful and upsetting, ii) leads to the in-
ability to act, iii) uncertain events are negative and should be avoided,
and iv) being uncertain is unfair. This 27 item scale includes items such
as “Uncertainty keeps me from living a full life” and “Unforeseen events
upset me greatly”. Participants rate each item on a five-point Likert
scale ranging from 1 = ‘not at all characteristic of me’, to 5 = ‘entirely
characteristic of me’. The IUS has demonstrated good test-retest relia-
bility over 5 weeks, r = 0.78 and has an excellent internal consistency,
a = 0.91.25, 26
Beck Anxiety Inventory (BAI): The BAI is a self-report scale designed
to evaluate the severity of physical symptoms of anxiety over the past
week.27,28 Participants rate the 21 items on a 4-point severity scale
from 0 = ‘not at all’ to 3 = ‘severely, I could barely stand it’. Total
response scores range from 0 to 63, with higher scores indicating more
severe anxiety. The BAI possesses adequate test-retest reliability and
convergent validity.29
Fawcett-Clark Pleasure Capacity Scale (FCPS): The FCPS is a 36-
item questionnaire assessing a participant’s current pleasure capacity
on a 5-point Likert scale.30 Participants are asked to rate their hedonic
responses to hypothetical situations regarding several areas such as
social activity, sensory experiences and sense of mastery of difficult
tasks. Higher scores for each item indicate a higher hedonic capacity.30
Although frequently administered to assess anhedonia, the reliability
and validity of this measure has not been widely studied.31 D’haenen.32
suggests its concurrent validity and reliability is satisfactory, while
Leventhal and colleagues demonstrate the FCPS to have a significant
factor loading from Hedonic Capacity.30
Sheehan Disability Scale (SDS): The SDS is a measurement of
functional disability and impairment due to psychiatric symptoms.33
The SDS is made up of 5 items that measure the extent a patient is
impaired by the disease. It evaluates 3 inter-correlated domains (work/
school, social life, and family life/home responsibilities) and measures
the number of unproductive or under-productive days. Each of the three
domains is rated from 0 to 10 (no impairment to most severe impair-
ment) with evaluation of not at all,0 mild,1–3 moderate,4–6 marked,7–9
and extreme.10 disability. A score of 30 indicates most severe impair-
ment.33
Additionally, safety was assessed at each visit using non-leading
questions such as “Have you felt different in any way since the last
visit?”. Serum vitamin D was reassessed at the study mid-point, final
visit and follow-up to ensure that levels did not exceed the re-
commended 150 nmol/L. Vital signs were reassessed at the study mid-
point, final visit and follow-up and a physical examination was repeated
at the final visit and follow-up.
2.6. Sample size determination
As this is a pilot study, a formal sample size calculation was not
possible. Responder (> 50% improvement on symptoms) rates from a
treatment resistant depression population vary widely, although one
study estimates this to be approximately 12% for patients receiving
‘usual care’34 We anticipated that the vitamin D group would experi-
ence an approximate 10 point reduction on their BDI scores, resulting in
approximately 20% achieving ‘responder' status. Using these effect size
estimates, and incorporating a Type 1 Error of 0.05, 80% power will be
achieved if 125 people are recruited. This plan allowed for up to a 25%
participant withdrawal/dropout rate and still ensured that the study
was adequately powered based on the assumptions outlined above.
2.7. Statistical analysis
In order to assess if there was a change in scores over time for both
groups while investigating covariates such as baseline serum vitamin D
and change in vitamin D levels over time, an ANOVA was to be con-
ducted. The primary outcome measure of interest was the change in
total depression measure scores (BDI-II scores) from baseline to the last
observed visit. This continuous efficacy variable comparison was ana-
lysed using a student’s t-test for between group differences and χ2 tests
for dichotomous variables (i.e., responder rates). Results generated by
the remaining (secondary) outcome measures were analysed using a t-
test. All parametric tests will be 2-tailed and calculated using a 5%
alpha level. Analyses were planned to be conducted on an intention to
treat basis using the last observation carried forward from all partici-
pants who received at least one administration of study product.
2.8. Protocol amendments
Due to slower than expected enrollment during the first season,
several amendments were made in an attempt to increase recruitment
and eligibility. Because of interest from older patients, the age range
was extended from 18 to 65 to 18–75 years of age. Subsequently, the
requirement for failing to respond to one pharmacologic antidepressant
agent was removed, thus including patients taking no medication or
multiple medications. Three additional tertiary psychiatric clinics were
added as trial sites to increase exposure. Finally, the protocol was
changed to reduce the burden on participants by changing the in-office
visits to bi-weekly and including a weekly phone call to assess for safety
and ongoing eligibility. All amendments were approved by Health
Canada and the Research Ethics Boards.
3. Results
Over three recruitment period years (October to April, from 2013 to
2016), a total of 148 individuals completed phone screening. At the
START Clinic, the primary study site, 40 individuals from the clinic
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database who were potentially eligible were contacted and offered an
opportunity to complete the phone screen. 3 individuals were referred
to the study by doctors – 2 by clinicians involved in the study and 1 by
local medical doctors. Patients responded to postings and advertise-
ments about the study on online classified pages (n = 34), the Canadian
College of Naturopathic Medicine website (n = 7), the Clinical Trials
Registry website (n = 4), in the newspaper (n = 16), the radio (n = 3)
and a poster displayed in local medical doctors’ offices (n = 8). Three
patients heard about the study word of mouth and 18 individuals did
not disclose a referral source or could not be contacted. At one addi-
tional site the two patients who completed screening were referred by a
study clinician and at the second, 23 patients were referred by a doctor
involved in the study and five were referred by doctors external to the
study. See Table 1 for a complete review of sources of subject recruit-
ment.
A complete visual outline of study protocol pathway and partici-
pants is shown in Fig. 1.
Of 179 inquiries and 148 individuals screened, 24 (16.2%) qualified
to participate in the study. The reasons for failing to qualify included:
medication (n = 51, 25 taking no medication, 20 taking multiple
medications, 4 recently changing medications, 2 taking a low dose of a
medication), lack of interest/time commitment in completing screening
questionnaire (n = 14), comorbidities (n = 23), age greater than 65
years (n = 5), current vitamin D supplementation (n = 17), not inter-
ested without compensation (n = 6), didn’t meet criteria for current
MDD (n = 3), not willing to travel to the clinic (n = 2), trying to
conceive (n = 1), no provincial insurance (n = 1). An additional 24
individuals who expressed interest could not be reached by phone and 7
individuals contacted the study outside of the recruiting season but
could not be re-contacted during recruiting. Table 2 outlines the spe-
cifics of why people were deemed ineligible.
Of the 24 individuals who qualified on the phone screen, 9 parti-
cipants were successfully enrolled in the study. The most common
reasons for unwillingness to participate included a lack of interest
(n = 12), scheduling conflict (n = 2) and loss to follow up (n = 1).
Table 3 outlines the baseline characteristics of the enrollees.
Of the 9 patients who enrolled, seven participants completed the
study (77.8% completion rate). One participant was withdrawn after 5
visits at the discretion of the study clinician due to subjective assess-
ment of worsening anxiety and depression symptoms and indication for
an increase in the participant’s medication dosage. A second patient
chose to withdraw after 3 study visits due to interest in participating in
another clinical trial; although randomized, they had not received any
study medication.
Aside from the participant that was withdrawn due to worsening of
the condition being studied, no other adverse events were reported. No
changes were observed on physical examination at the midpoint or
conclusion of the study. No participants had midpoint or final serum
vitamin D levels that exceeded 150 nmol/L, a level which has been
deemed to be toxic or associated with significant risk.35
After the third season, futility was declared based on inability to
enroll participants. The sample size of enrolled participants (7/125,
5.6%) lacks power to conduct a full assessment of findings. A pre-
liminary assessment of the available data shows a trend towards im-
provement in BDI, BAI, FCPCS and SDS scores; however, very high le-
vels of variability among the small number of participants precludes
any conclusions. Mean scores, using the last observation carried for-
ward, are presented in Table 4. Additionally, among participants who
completed the study, meaningful increases in serum vitamin D levels
were observed.
4. Discussion
The question of the role of vitamin D in the development and pro-
gression of mood disorders is relevant and warrants thorough in-
vestigation. While this study was not able to answer the question of this
nutrient’s clinical utility, the challenges that it faced highlight some of
the difficulties of assessing vitamin D as an intervention in the non-
remitted depression population and may serve to guide future clinical
trials in this area. Clinical trials with low enrollment deplete resources
and increase costs and delay the availability of clinical information.36
There were many factors that may have contributed to the difficulty
experienced in recruiting and enrolling patients. Some of the challenges
could be related to using vitamin D as an intervention. There is a
growing lack of equipoise among patients and clinicians about the
potential ubiquitous benefits of vitamin D for Canadians, not just for
mood disorders. Numerous guidelines have been produced in recent
years.37 including a 2007 recommendation from Health Canada to
supplement 400IU of vitamin D in all adults 50 years of age or older. In
the same year, the Canadian Cancer Society recommended 1000IU of
vitamin D supplementation for all Canadian adults and 2010 re-
commendations from Osteoporosis Canada included supplementation of
400 to 2000IU of vitamin D for bone health promotion based on risk
level38 Further, a Cochrane review suggested that vitamin D supple-
mentation in an elderly population may decrease all-cause mortality.39
Vitamin D deficiency has received widespread media attention and
many consumers are choosing to purchase supplements which are
widely available, accessible without a prescription and low in cost. A
recent study estimated that in 2007–2009, 31% of Canadians had taken
a vitamin D-containing supplement in the prior month.40 Because cur-
rent vitamin D supplementation was an exclusionary criterion in this
protocol, many individuals were deemed ineligible. Furthermore, with
the growing public perception that vitamin D may be helpful in main-
taining mood, particularly in the winter, the draw of a potentially novel
treatment may not have been present in this study to outweigh the
possibility of being randomized to receive the placebo formula. A recent
study assessing participant motivations for participation in a clinical
trial found that 91.4% expected to personally benefit from the study.41
In this case, individuals expecting to benefit from vitamin D had the
option of easily purchasing the nutrient rather than participating in a
study involving multiple clinic visits, blood draws and the possibility of
placebo allocation. Additionally, the prominent motivation of personal
gain from participation may have also limited the participation of in-
dividuals who did not believe that vitamin D was a potentially useful
therapy. One patient who declined participation reported that he was
“skeptical of vitamin D” and others sharing similar beliefs may have
chosen not to contact the study.
Many challenges arose as a result of the patient population selected
for this study. Conducting research in patients with depression is
challenged by a heterogeneous population, a lack of biomarkers and
high rates of comorbidity.42 While the non-remitted depression popu-
lation allows for ethical use of an unproven therapeutic agent as an
adjunctive treatment, there were limitations. Non-remitted depression,
like other mood disorders often follows a progression or relapsing and
remitting.43 Treatment-resistant depression is known to have a more
complex clinical course than treatment-sensitive depression.2 Despite
reporting ongoing depression, some patients failed to meet the criteria
Table 1
Referral sources for individuals screened for participation, all study sites combined.
Referral Source Number of Individuals
Referral by a study doctor 40
START Clinic Database 40
Online classified posting 34
Unknown 18
Newspaper Advertisement 16
Posters in local doctors’ offices 8
Canadian College of Naturopathic Medicine website 7
Referral by an external doctor 6
Clinical Trials Registry website 4
Word of mouth 3
Radio 3
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for MDD at the time of screening for this study. Conversely, some ex-
perienced aggravation in their symptoms around the time of screening
and were prescribed additional new therapies or adjustments to their
pharmacotherapy protocol which excluded them from participation as
the new medication would have added a degree of difficulty in inter-
preting results.
Another challenge to recruitment was a high frequency of comorbid
conditions in the patients screened for eligibility. In order to assess the
role of vitamin D in depression and avoid confounding factors, we
sought to exclude other psychiatric conditions; however, the number of
individuals who met Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition criteria for another psychiatric diagnosis
when completing the MINI was significant. This may have been a result
of the patient population of this study. Patients with treatment-resistant
depression have higher rates of Axis I, II and III disorders compared to
patients with treatment-sensitive depression, with particularly high
rates of comorbid anxiety and substance use disorders.2 A recent study
found that a significant number of patients who failed to respond to
antidepressant medication may have undetected bipolar disorder.2,44
The high rates of comorbid psychiatric conditions may also be re-
lated to the clinical population seen at the primary clinic where re-
cruiting took place. As a tertiary psychiatry clinic, many patients
Fig. 1. Enrollment and involvement pathway, CONSORT Flow Diagram.
Table 2
Reasons for failing to qualify for enrollment.
Reason for failing to qualify Number of Individuals
Medication 51
Comorbid psychiatric condition 23
Current Vitamin D Supplementation 17
Not interested 14
Seeking compensation 6
Age (above limit) 5
No current MDD 3
Travel concerns 2
Trying to conceive 1
No OHIP card 1
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referred to the clinic have multiple psychiatric diagnoses. Recruiting
from a primary care setting may allow for a greater numbers of re-
spondents without comorbidities.
Additionally, the combination of this patient population with a
placebo arm may have contributed to the recruitment difficulty. Since
this population was already dealing with a long duration of illness and
had failed to see benefit from one treatment, we hypothesize that they
may have been less tolerant of potential enrollment in the inactive
placebo arm and a lack of additional treatment for 3 months. Another
clinical trial, although in a unique patient population, found this to be
the case in individuals who failed previous interventions.45
The factor that resulted in exclusion of the highest number of po-
tential participants was the requirement for using one psychiatric
medication as many individuals were taking no medications, multiple
medications, low doses of medication or recently changed prescriptions.
The high rates of these cases may be related to the non-remitted de-
pression populations as a result of comorbidities, relapsing and remit-
ting symptoms and sequential additions of therapies in response to
failure to remit.
One additional challenge faced by the study was the limited funding
available to studies assessing natural health products. A lack of hon-
orarium for time and travel was cited by many individuals as the reason
for declining screening or participation. Funding also limited the
amount of advertisements needed to reach potentially eligible in-
dividuals. A recent study assessed motivation factors for healthy vo-
lunteers to participate in a randomized trial and found that 87.6% were
motivated to support medical research while, lack of financial com-
pensation was reported by a minority of individuals as a reason for
declining to participate.46 A small study that explored the motivations
of patients with depression found that a desire to help others or further
science was reported most frequently.47 While this suggests that moti-
vation to participate may not be primarily dependent on financial
compensation, the frequency with which this concern was cited by
potential candidates suggests that this may be a factor that warrants
consideration although additional practical and ethical considerations
arise regarding participant remuneration and payment for participating
in clinical trials.48
The study was designed to have individuals participate during the
winter months when vitamin D levels are lowest.40 in order to increase
the likelihood of observing a benefit from increasing serum levels
through supplementation. Additionally, concern about time of year as a
confounding variable in the study led to this decision. However,
starting and stopping the study annually posed difficulty. Some patients
contacted the study outside of the recruiting season or too close to the
end of the season to allow time to complete the study but were no
longer able to be reached, were no longer interested, or no longer
qualified when recruiting resumed. A 2011 Canadian study found an
average difference of only 6nmol/L between summer and winter40 This
may be related to poor synthesis due to skin pigmentation in some in-
dividuals or limited summer sun exposure or to lifestyle factors that
increase endogenous production during the winter months such as use
of tanning beds or travel to Southern vacation locations which are
noted to be common among Canadians.40 Although this finding war-
rants confirmation, it suggests that the season may not have as large an
impact as investigators may think and the benefit of year-round re-
cruitment might be considered to enhance study feasibility. Subgroup
analysis based on season of enrollment or use of a statistical model to
estimate the contribution of sun exposure to participant vitamin D le-
vels may be employed or considered in future studies.
The recruitment and enrollment challenges faced by this study may
have been related to one of the above factors or a combination of fac-
tors. Future studies may benefit from our experiences in design and
conduct of research. Because many patients are already choosing to
supplement vitamin D or have already been prescribed this treatment,
designing a protocol that allows for inclusion of these individuals may
be beneficial for recruitment. A recent Canadian study found that while
the prevalence of vitamin D deficiency in nonusers of vitamin D sup-
plements was double the rate in supplement users (30.4% compared to
15.4%), the users still had a significant rate of deficiency. Designing a
trial which accepts patients already using vitamin D but not achieving
an optimal target value may be a feasible option. This methodology was
used by another Canadian study which recruited patients based on low
serum levels of vitamin D and did not enquire about intake of supple-
ments.21 Alternately a four-arm study could be designed in which pa-
tients with adequate or inadequate vitamin D are randomized to receive
either vitamin D or placebo. No studies assessing the role of vitamin D
in depression have elucidated the respective roles of current supple-
mentation compared to serum adequacy. This issue is further con-
founded by emerging research involving genetic polymorphisms asso-
ciated with the vitamin D receptor, vitamin D (in)sufficiency, and the
potential to influence development or successful treatment approaches
in depression.49–51
A recent study conducted by a Canadian university aggregated data
from 14,000 participants on the effects of supplement dosage on serum
vitamin D concentrations. They found that the daily dose needed for
97.5% of the population to achieve a serum level of at least 50 nmol/L
was 2909 IU.52 Many patients currently taking vitamin D supplements
are taking much lower doses, as suggested by the guidelines cited above
and a study that employs a higher dose in order to significantly increase
serum status may be warranted. A study comparing low and high dose
vitamin D supplementation, as used in another study,21 could allow for
inclusion of individuals already supplementing with low doses and
Table 3





BMI at Enrollment (kg/m2 ± SD) 33.0 ± 8.9
Average Age at Enrollment (years ± SD) 46.6 ± 11.6
Level of Education (%)
high school or less 33
bachelor or collage 44






Time since first depression episode (years ± SD) 17.3 ± 12.0
Taking antidepressant medication (%) 100
Concurrent anxiety disorder (%) 55
Average BDI Score at Enrollment (± SD) 18.6 ± 16.3
Minimal depression (BDI-II: 0–13) (%) 56
Mild depression (BDI-II: 14–19) (%) 0
Moderate depression (BDI-II: 20–28) (%) 22
Severe depression (BDI-II: 29–63) (%) 22
Average BAI Score at Enrollment (± SD) 13.6 ± 14.4
Minimal anxiety (BAI: 0–7) (%) 44
Mild anxiety (BAI: 8–15) (%) 33
Moderate anxiety (BAI: 16–25) (%) 11
Severe anxiety (BAI: 26–63) (%) 11
Baseline Serum 25-OHD (nmol/L ± SD) 50.6 ± 17.1
Table 4
Mean assessment tool scores and serum vitamin D levels at baseline and final visit.
Assessment Tool Baseline (Mean ± SD) Final (Mean ± SD)
BDI 18.6 ± 16.3 14.78 ± 12.19
BAI 13.6 ± 14.4 12.9 ± 17.4
IUS 80.9 ± 29.2 94.0 ± 33.7
FCPCS 130.6 ± 29.8 138.1 ± 40.5
SDS 15.2 ± 8.4 11.6 ± 9.9
Serum Vitamin D (nmol/L) 50.6 ± 17.1 83.3 ± 18.1
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avoid the deterrent of potential randomization to the placebo arm.
Preference trials may be employed to account for the preferences
both for and against vitamin D that were evident in the population
screened. This type of trial could compare adjunctive vitamin D to
conventional psychiatric management with sequential pharmacologic
agents. This may allow recruitment of individuals not interested in vi-
tamin D supplementation as part of the control group and decrease the
deterring effect of possible placebo allocation in those interested in
vitamin supplementation.
Other clinical trials assessing vitamin D in patients with depression
have been able to recruit adequate numbers of participants however
many of these utilized broader clinical populations, healthy subjects or
health professionals. One study, which also employed vitamin D as an
adjunct therapy to psychopharmacology, randomized patients diag-
nosed with MDD to either fluoxetine or fluoxetine plus vitamin D,13
This allows for study of the nutrient as an adjunctive therapy without
utilizing a non-remitted depression population to avoid some of the
challenges of high comorbidities, recent medication changes or mul-
tiple psychiatric medications.
This report has a number of limitations. While we are able to report
on the reasons for not qualifying or declining participation, we can only
report these for the individuals who responded to our advertisements or
were able to be contacted. Individuals who chose not to contact the
study for any of the reasons discussed above could not be accounted for.
Additionally, when individuals were screened for eligibility, the phone
screen was completed until the individual provided a response that
made them ineligible. As such, individuals may have had multiple
reasons for failing to qualify but only the first in the sequence of
questions is reported. Questions asked early in the screen included
willingness to participate without compensation, age, current medica-
tion, vitamin D supplementation; these may be over-represented in the
reasons for failing to qualify. The later part of the phone screen assesses
for comorbidities; these may be under-represented in our data.
5. Conclusions
The role of vitamin D as a therapeutic agent in the treatment of non-
remitted major depressive disorder shows promise but continues to be
unknown. This study highlights some of the challenges of this inter-
vention and study population and may provide guidance in the design
and conduct of other similar studies in the future to increase the like-
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